DE69530594D1 - Verfahren und mittel zur arzneistoffverabreichung - Google Patents

Verfahren und mittel zur arzneistoffverabreichung

Info

Publication number
DE69530594D1
DE69530594D1 DE69530594T DE69530594T DE69530594D1 DE 69530594 D1 DE69530594 D1 DE 69530594D1 DE 69530594 T DE69530594 T DE 69530594T DE 69530594 T DE69530594 T DE 69530594T DE 69530594 D1 DE69530594 D1 DE 69530594D1
Authority
DE
Germany
Prior art keywords
pct
nerve head
sec
drug
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69530594T
Other languages
English (en)
Other versions
DE69530594T2 (de
Inventor
Johan Stjernschantz
Goeran Selan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of DE69530594D1 publication Critical patent/DE69530594D1/de
Application granted granted Critical
Publication of DE69530594T2 publication Critical patent/DE69530594T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/557Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE69530594T 1994-08-24 1995-08-24 Verfahren und mittel zur arzneistoffverabreichung Expired - Fee Related DE69530594T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9402816A SE9402816D0 (sv) 1994-08-24 1994-08-24 Method and meams for drug administration
SE9402816 1994-08-24
PCT/SE1995/000962 WO1996005840A1 (en) 1994-08-24 1995-08-24 Methods and means for drug administration

Publications (2)

Publication Number Publication Date
DE69530594D1 true DE69530594D1 (de) 2003-06-05
DE69530594T2 DE69530594T2 (de) 2004-03-18

Family

ID=20395002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69530594T Expired - Fee Related DE69530594T2 (de) 1994-08-24 1995-08-24 Verfahren und mittel zur arzneistoffverabreichung

Country Status (12)

Country Link
US (1) US5952378A (de)
EP (1) EP0777483B1 (de)
JP (1) JPH10507743A (de)
AT (1) ATE238799T1 (de)
AU (1) AU3402295A (de)
CA (1) CA2198245C (de)
DE (1) DE69530594T2 (de)
DK (1) DK0777483T3 (de)
ES (1) ES2199253T3 (de)
PT (1) PT777483E (de)
SE (1) SE9402816D0 (de)
WO (1) WO1996005840A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
EP1977724A1 (de) 2001-04-07 2008-10-08 Glaukos Corporation System zur Behandlung von Augenstörungen
WO2002085248A2 (en) * 2001-04-23 2002-10-31 Board Of Regents The University Of Texas System Prostanoids augment ocular drug penetration
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
AU2002305400A1 (en) 2001-05-03 2002-11-18 Glaukos Corporation Medical device and methods of use for glaucoma treatment
EP1410808A4 (de) * 2001-07-02 2009-07-29 Santen Pharmaceutical Co Ltd Mittel zum schutz des sehnervs mit alpha-1-rezeptor-blocker als wirkstoff
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7163543B2 (en) * 2001-11-08 2007-01-16 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
ES2319399T3 (es) 2001-12-14 2009-05-07 Alcon, Inc. Compuestos mimeticos de la superoxido-dismutasa para el tratamiento de trastornos y enfermedades oculares.
US20030113270A1 (en) * 2001-12-14 2003-06-19 Clark Abbot F. Vasoactive intestinal peptides for glaucomatous retinopathy
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
WO2004026347A2 (en) * 2002-09-17 2004-04-01 Iscience Surgical Corporation Apparatus and method for surgical bypass of aqueous humor
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
EP1663230A1 (de) * 2003-09-05 2006-06-07 Novartis AG Zusammensetzungen mit benzo(g)chinolin-derivaten und prostaglandin-derivaten
KR20060101501A (ko) 2003-12-11 2006-09-25 알콘, 인코퍼레이티드 시신경 및 망막 손상의 치료를 위한 슈퍼옥사이드디스무타제 유사체
ZA200609408B (en) * 2004-04-29 2008-02-27 Iscience Interventional Corp Apparatus and method for surgical enhancement of aqueous humor drainage
US8322350B2 (en) 2004-12-30 2012-12-04 Philip Morris Usa Inc. Aerosol generator
EP1848541A4 (de) * 2005-02-07 2013-01-16 Pharmalight Inc Verfahren und vorrichtung zur ophthalmischen verabreichung von pharmazeutischen wirksstoffen
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US7625927B2 (en) * 2006-02-27 2009-12-01 Alcon Research, Ltd. Method of treating glaucoma
US8506515B2 (en) 2006-11-10 2013-08-13 Glaukos Corporation Uveoscleral shunt and methods for implanting same
CA2698695A1 (en) * 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US20100191177A1 (en) * 2009-01-23 2010-07-29 Iscience Interventional Corporation Device for aspirating fluids
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
JP5342301B2 (ja) * 2009-03-30 2013-11-13 三菱重工業株式会社 太陽光集光受熱器
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
CN104758118B (zh) 2010-10-15 2018-04-06 科尼尔赛德生物医学公司 用于进入眼睛的装置
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
EP2755549A1 (de) 2011-09-13 2014-07-23 Dose Medical Corporation Intraokularer physiologischer sensor
CN104884049A (zh) 2012-11-08 2015-09-02 克莱尔塞德生物医学股份有限公司 用于在人类受试者中治疗眼部疾病的方法和装置
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
CN110302004B (zh) 2013-05-03 2023-04-28 科尼尔赛德生物医学公司 用于眼部注射的设备和方法
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
JP2017524419A (ja) 2014-06-20 2017-08-31 クリアサイド バイオメディカル,インコーポレイテッド 薬剤送達のための挿入深さを制御するための可変径カニューレ及び方法
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
WO2017139375A1 (en) 2016-02-10 2017-08-17 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
AU2017252294B2 (en) 2016-04-20 2021-12-02 Dose Medical Corporation Bioresorbable ocular drug delivery device
CA3062845A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的***深度的装置和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2042625T5 (es) * 1987-04-03 2000-07-16 Univ Columbia Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.

Also Published As

Publication number Publication date
DK0777483T3 (da) 2003-08-25
EP0777483A1 (de) 1997-06-11
US5952378A (en) 1999-09-14
CA2198245C (en) 2003-06-17
CA2198245A1 (en) 1996-02-29
WO1996005840A1 (en) 1996-02-29
AU3402295A (en) 1996-03-14
EP0777483B1 (de) 2003-05-02
JPH10507743A (ja) 1998-07-28
ATE238799T1 (de) 2003-05-15
SE9402816D0 (sv) 1994-08-24
ES2199253T3 (es) 2004-02-16
PT777483E (pt) 2003-09-30
DE69530594T2 (de) 2004-03-18

Similar Documents

Publication Publication Date Title
DE69530594D1 (de) Verfahren und mittel zur arzneistoffverabreichung
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
ATE264671T1 (de) Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
DE69433713D1 (de) Für die behandlung neurologischer erkrankungen nützliche methoden und pharmazeutische zusammensetzungen
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
DK0850068T3 (da) Lipidekstrakt med antiinflammatorisk aktivitet
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE60134453D1 (de) Pharmazeutische Zusammensetzungen zur Behandlung von ZNS und anderen Krankheiten
YU209288A (en) Process for producing compound for treating, which contains azelastin for use in nose and/or eye
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
BR9407748A (pt) Formulação farmacéutica processo para preparação da mesma e processo para a prevenção e/ou o tratamento de neurodegeneração ou para a obtenção de um efeito anti-convulsivo ou sedação em um paciente
ES2173111T3 (es) Uso de fenserina para la preparacion de medicamentos para el tratamiento de desordenes cognoscitivos.
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
BR9813318A (pt) Processo de tratamento de tumores e degeneração macular em paciente humano ou veterinário, composição farmacêutica para tratamento de tumores e degeneração macular em um paciente humano ou veterinário
TR200000149T2 (tr) Serebral nörovasküler bozuklukların, müsküler baş ağrılarının önlenmesine yönelik kompozisyonlar
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
BR9607541A (pt) Tratamento de doenças que tem por causa o fator de crescimento da citoquina
ES2096207T3 (es) Prevencion y tratamiento de aterosclerosis.
DE69733169D1 (de) Verwendung von Alpha-1-Adrenorezeptor-Antagonisten zur Herstellung eines Medikaments für die Vorbeugung und die Behandlung von Krebs
DK0871446T3 (da) Anvendelse af eliprodil til fremstilling af et lægemiddel til behandling af ischaemiske sygdomme i nethinden eller den optiske nerve
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
SE9000207D0 (sv) Laekemedel samt anvaendningen av detsamma
SE9101341D0 (sv) New medicinal use

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee